| [1] |
|
| [2] |
|
| [3] |
Thomas L, Sadick N.A case of Fabry disease mimicking hypertrophic cardiomyopathy[J]. Heart Lung Circ, 2004, 13(2):188-190.DOI: 10.1016/j.hlc.2004.01.030.
|
| [4] |
Saito S, Ohno K, Sakuraba H.Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A[J]. PLoS One, 2013, 8(12):e84267.DOI: 10.1371/journal.pone.0084267.
|
| [5] |
Seo J, Kim M, Hong GR, et al. Fabry disease in patients with hypertrophic cardiomyopathy:a practical approach to diagnosis[J]. J Hum Genet, 2016, 61(9):775-780.DOI: 10.1038/jhg.2016.52.
|
| [6] |
Lin Z, Zhang X, Liu Y, et al. Screening for Fabry disease in patients with left ventricular hypertrophy in China:a multicenter and prospective study[J]. ESC Heart Fail, 2024, 11(6):4381-4389.DOI: 10.1002/ehf2.15065.
|
| [7] |
|
| [8] |
Chen X, Qiu W, Ye J,et al.Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China[J]. J Hum Genet, 2016, 61(4):345-349.DOI: 10.1038/jhg.2015.155.
|
| [9] |
潘晓霞,欧阳彦,王朝晖,等.法布里病83例临床病理特点分析[J].中国实用内科杂志,2014,34(3):262-266.
|
| [10] |
|
| [11] |
|
| [12] |
Rozenfeld P, Feriozzi S.Contribution of inflammatory pathways to Fabry disease pathogenesis[J]. Mol Genet Metab, 2017, 122(3):19-27.DOI: 10.1016/j.ymgme.2017.09.004.
|
| [13] |
|
| [14] |
Cocozza S, Russo C, Pontillo G, et al. Neuroimaging in Fabry disease:current knowledge and future directions[J]. Insights Imaging, 2018, 9(6):1077-1088.DOI: 10.1007/s13244-018-0664-8.
|
| [15] |
|
| [16] |
Cortés-Saladelafont E, Fernández-Martín J, Ortolano S. Fabry disease and central nervous system involvement:from big to small,from brain to synapse[J]. Int J Mol Sci, 2023, 24(6):5246.DOI: 10.3390/ijms24065246.
|
| [17] |
Scaravilli A, Capasso S, Ugga L,et al.Clinical and pathophysiologic correlates of basilar artery measurements in Fabry disease[J]. AJNR Am J Neuroradiol, 2024, 45(11):1670-1677.DOI: 10.3174/ajnr.A8403.
|
| [18] |
Manara R, Carlier RY, Righetto S,et al.Basilar artery changes in Fabry disease[J]. AJNR Am J Neuroradiol, 2017, 38(3):531-536.DOI: 10.3174/ajnr.A5069.
|
| [19] |
|
| [20] |
Favalli V, Disabella E, Molinaro M, et al. Genetic screening of Anderson-Fabry disease in probands referred from multispecialty clinics[J]. J Am Coll Cardiol, 2016, 68(10):1037-1050.DOI: 10.1016/j.jacc.2016.05.090.
|
| [21] |
Camporeale A, Diano A, Tondi L,et al.Cardiac magnetic resonance features of Fabry disease:from early diagnosis to prognostic stratification[J]. Rev Cardiovasc Med, 2022, 23(5):177.DOI: 10.31083/j.rcm2305177.
|
| [22] |
Sado DM, White SK, Piechnik SK,et al.Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping[J]. Circ Cardiovasc Imaging, 2013, 6(3):392-398.DOI: 10.1161/CIRCIMAGING.112.000070.
|
| [23] |
Messroghli DR, Moon JC, Ferreira VM,et al.Clinical recommendations for cardiovascular magnetic resonance mapping of T 1,T 2,T 2* and extracellular volume:a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J]. J Cardiovasc Magn Reson, 2017, 19(1):75.DOI: 10.1186/s12968-017-0389-8.
|
| [24] |
Camporeale A, Pieroni M, Pieruzzi F,et al. Predictors of clinical evolution in prehypertrophic Fabry disease[J]. Circ Cardiovasc Imaging, 2019, 12(4):e008424.DOI: 10.1161/CIRCIMAGING.118.008424.
|
| [25] |
Camporeale A, Moroni F, Lazzeroni D,et al.Trabecular complexity as an early marker of cardiac involvement in Fabry disease[J]. Eur Heart J Cardiovasc Imaging, 2022, 23(2):200-208.DOI: 10.1093/ehjci/jeaa354.
|
| [26] |
Karur GR, Mathur S, Morel CF,et al.Increased spread of native T 1 values assessed with MRI as a marker of cardiac involvement in Fabry disease[J]. AJR Am J Roentgenol, 2021, 216(2):355-361.DOI: 10.2214/AJR.20.23102.
|